Month: August 2022

REMINDER/KP Tissue to Release its Financial Results and those of Kruger Products L.P. for the Second Quarter of 2022

Written by Customer Service on August 10, 2022. Posted in Public Companies.

MISSISSAUGA, Ontario, Aug. 10, 2022 (GLOBE NEWSWIRE) — KP Tissue Inc. (“KPT”) (TSX:KPT), which holds a limited partnership interest in Kruger Products L.P. (“KPLP”), will release the financial results for KPT and KPLP for the second quarter of 2022 on Thursday, August 11 before the market opens. KPT will hold its conference call the same day at 8:30 a.m. Eastern Time. Details of the Conference Call Via telephone: 1-888-396-8049 or 416-764-8646Via the internet at: www.kptissueinc.com Presentation material referenced during the conference call will be available at www.kptissueinc.com Conference Call Rebroadcast A rebroadcast of the conference call will be available until midnight, August 18, 2022 by dialing 1-877-674-7070 or 416-764-8692 and entering passcode 464389. The replay of the webcast will remain available on the web site...

REMINDER/Supremex Announces Date of Its 2022 Second Quarter Results Conference Call

Written by Customer Service on August 10, 2022. Posted in Public Companies.

MONTREAL, Aug. 10, 2022 (GLOBE NEWSWIRE) — Supremex Inc. (“Supremex” or the “Company”) (TSX: SXP), a leading North American manufacturer and marketer of envelopes and a growing provider of paper-based packaging solutions, will release its results for the Second quarter ended June 30, 2022, before markets open on Thursday, August 11, 2022. A conference call to discuss these results will be held on the same day, at 11:00 a.m. (Eastern Time). Conference Call: A live broadcast of the Conference Call will be available on the Company’s website, in the Investors section under Webcast. To participate (professional investment community only) or to listen to the live conference call, please dial the following numbers. We suggest that participants call-in at least 5 minutes prior to the scheduled start time:• Confirmation number: 66330361• Local...

Verde achieves 782% EBITDA and 362% revenue growths in Q2 2022

Written by Customer Service on August 10, 2022. Posted in Earnings Releases And Operating Results.

(All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in Q2 2022: C$1.00 = R$3.99) BELO HORIZONTE, Brazil, Aug. 10, 2022 (GLOBE NEWSWIRE) — Verde AgriTech Ltd (TSX: “NPK”) (“Verde” or the “Company”) is pleased to announce its financial results for the second quarter of 2022 (“Q2 2022”). Q2 2022 FINANCIALSRevenue increased by 362% in Q2 2022, to $24,861,000 compared to $5,376,000 in Q2 2021. Revenue in Brazilian Real (“R$”) increased by 327% in Q2 2022, to R$99,185,000 compared to R$23,215,000 in Q2 2021. Sales of Verde’s multinutrient potassium products, BAKS® and K Forte® sold internationally as Super Greensand® (the “Product”) by volume increased by 112% in Q2 2022, to 202,255 tonnes, compared to 95,551 tonnes sold in Q2 2021. Gross margin increased to 79% in Q2 2022, compared to 72%...

SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results

Written by Customer Service on August 10, 2022. Posted in Earnings Releases And Operating Results.

Expects cash is sufficient to fund operations for the forward twelve months SIOUX FALLS, S.D., Aug. 10, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the second quarter ended June 30, 2022 and provided a company update. “We continue to utilize our capabilities and infrastructure to advance our development pipeline in immunotherapeutics directed at unmet medical needs in influenza and Clostridioides difficile (C. diff.) as well as discovery programs in autoimmune disease and oncology. Furthermore, with the validation of our technology in clinical trials in the last year, we are...

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones

Written by Customer Service on August 10, 2022. Posted in Earnings Releases And Operating Results.

Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on trackISELIN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced its financial results for its fiscal third quarter ended June 30, 2022, provided recent corporate highlights, and reiterated its anticipated near-term milestones. Recent Corporate HighlightsAnnounced the full cash pre-payment of its $12.3 million unsecured convertible promissory note dated November 4, 2020, as amended November 16, 2021; and Confirmed plans to re-submit ONS-5010 BLA by September 2022.“We...

Crawford United Corporation Announces Second Quarter 2022 Results

Written by Customer Service on August 10, 2022. Posted in Earnings Releases And Operating Results.

Sales of $31.9 million for the quarter, an increase of 21% over Q2 2021 Sales of $62.9 million for the six-month period, an increase of 25% over 2021 Completed the acquisition of Knitting Machinery Company of AmericaCLEVELAND, Aug. 10, 2022 (GLOBE NEWSWIRE) — Crawford United Corporation (OTC: CRAWA), a growth-oriented holding company serving diverse markets, today reported results for the three-month and six-month periods ended June 30, 2022. For the quarter ended June 30, 2022, sales were $31.9 million compared to $26.4 million in the same period last year, an increase of 21%. In this quarter, the Company recorded operating income of $2.4 million compared to $2.1 million in the same period last year, an increase of 12%. Net income was $1.2 million, or $0.34 per fully diluted share, compared to $1.2 million, or $0.37 per fully...

BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights

Written by Customer Service on August 10, 2022. Posted in Earnings Releases And Operating Results.

Revenue Growth of 14% Year-over-Year in Q2 2022 Conference call to be held today, August 10, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 10, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported second quarter 2022 financial results and provided an operational update. Recent Financial and Operational HighlightsFor the three months ended June 30, 2022, revenues were $8.0 million, a 14% increase as compared to the prior year period. As of June 30, 2022, BrainsWay’s Deep TMS™ installed base was 829 total systems, a 22% increase from the installed base at the same point in the prior year. As of June 30, 2022, the Company had shipped 368 obsessive-compulsive disorder (OCD) coils as add-on...

Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Written by Customer Service on August 10, 2022. Posted in Earnings Releases And Operating Results.

Completed enrollment for Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy; topline data now expected to be presented in early Q1 2023 Presented positive 12-week interim analysis of Phase 2 study of MAU868 in kidney transplant recipients with BK Virus viremia at American Transplant Congress in June 2022; expect to initiate a Phase 2b or Phase 3 clinical trial in 2023 Strong balance sheet with approximately $131.9 million in cash, cash equivalents, and marketable securities as of June 30, 2022 and access to a $45.0 million credit facility expected to fund operations to Q2 2024BRISBANE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases,...

Aspira Women’s Health Reports Second Quarter 2022 Financial Results

Written by Customer Service on August 10, 2022. Posted in Earnings Releases And Operating Results.

Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz for development of a diagnostic test for endometriosis Reduced cash utilization by $3.9 Million in the Second Quarter 2022 Conference Call and Webcast scheduled for today, August 10th at 8:30 a.m. ET AUSTIN, Texas, Aug. 10, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2022. “We are pleased by our continued progress and execution during the second quarter, particularly on our three key strategic initiatives: Growth,...

Pipestone Energy Corp. Reports Record Second Quarter 2022 Results and Provides an Operations Update

Written by Customer Service on August 10, 2022. Posted in Earnings Releases And Operating Results.

Figure 1 Development MapCALGARY, Alberta, Aug. 10, 2022 (GLOBE NEWSWIRE) — (PIPE – TSX) Pipestone Energy Corp. (“Pipestone” or the “Company”) is pleased to report its second quarter 2022 financial and operational results, and to provide an update on its operations. SECOND QUARTER 2022 CORPORATE HIGHLIGHTS:The Company generated record revenue of $210.4 million, which represents more than a two and a half times increase over Q2 2021 revenue of $82.3 million, and a 37% increase from Q1 2022 revenue of $153.5 million; In Q2 2022, Pipestone achieved record average quarterly production totaling 30,770 boe/d (28% condensate, 41% total liquids), representing a 32% quarterly increase over Q2 2021 production of 23,336 boe/d (31% condensate, 46% total liquids), and a 12% increase over Q1 2022 production of 27,581 boe/d (29% condensate,...

Month: August 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals